May Gallardo serves as the Senior Director of Finance at Kartos Therapeutics, Inc., where she leverages over 15 years of extensive experience in finance and consulting within the technology and life sciences sectors. In her current role, May is pivotal in driving the financial and...
May Gallardo serves as the Senior Director of Finance at Kartos Therapeutics, Inc., where she leverages over 15 years of extensive experience in finance and consulting within the technology and life sciences sectors. In her current role, May is pivotal in driving the financial and accounting operations of the organization, ensuring that robust policies and procedures are established to support the company’s strategic objectives. Her expertise in strategic financial planning and business analysis enables her to lead the financial close process effectively, ensuring accuracy and compliance with Generally Accepted Accounting Principles (GAAP).
May is instrumental in overseeing critical functions such as banking, payroll activities, and audit engagements, as well as managing tax preparation and reporting. Her leadership in establishing and maintaining internal controls and reporting systems is vital for the organization’s financial integrity and operational efficiency. Additionally, she plays a key role in the quarterly forecasting process, collaborating with cross-functional teams to provide actionable insights that inform executive decision-making.
Her proficiency in program management and ERP implementations further enhances her ability to streamline financial operations, driving both efficiency and effectiveness across the organization. May’s analytical skills and business strategy acumen allow her to quickly dissect complex business challenges, delivering actionable recommendations that resonate with C-level executives and global business partners. As a forward-thinking finance leader, she is committed to fostering a culture of continuous improvement and strategic alignment at Kartos Therapeutics, positioning the company for sustained growth and success in the competitive life sciences landscape.
